Short Interest in Femasys Inc. (NASDAQ:FEMY) Decreases By 8.9%

Femasys Inc. (NASDAQ:FEMY) saw a significant decline in short interest in July. As of July 15th, there was short interest totalling 920,600 shares, a decline of 8.9% from the June 30th total of 1,010,000 shares. Currently, 4.5% of the shares of the company are short sold. Based on an average daily trading volume, of 171,000 shares, the short-interest ratio is currently 5.4 days.

Femasys Price Performance

Shares of NASDAQ FEMY remained flat at $1.13 during trading on Thursday. 124,058 shares of the stock traded hands, compared to its average volume of 418,777. The firm’s fifty day simple moving average is $1.12 and its two-hundred day simple moving average is $1.29. Femasys has a 1-year low of $0.25 and a 1-year high of $4.75. The firm has a market capitalization of $25.11 million, a price-to-earnings ratio of -1.32 and a beta of -2.81. The company has a quick ratio of 8.02, a current ratio of 8.43 and a debt-to-equity ratio of 0.29.

Femasys (NASDAQ:FEMY) last announced its earnings results on Thursday, May 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.05. The business had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.30 million. Femasys had a negative net margin of 1,420.59% and a negative return on equity of 104.06%. On average, analysts anticipate that Femasys will post -0.72 earnings per share for the current year.

Hedge Funds Weigh In On Femasys

A hedge fund recently raised its stake in Femasys stock. Clear Creek Financial Management LLC raised its position in Femasys Inc. (NASDAQ:FEMY) by 30.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 309,274 shares of the company’s stock after purchasing an additional 72,505 shares during the quarter. Clear Creek Financial Management LLC owned about 1.40% of Femasys worth $479,000 as of its most recent SEC filing. 65.27% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Femasys in a report on Thursday, June 20th.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.